Zacks Research Forecasts OPKO Health FY2028 Earnings

Key Points

• Zacks Research forecasts FY2028 EPS of ($0.16) for OPKO Health, compared with the current consensus of ($0.25), implying a smaller expected loss than the street.
• Analyst sentiment is mixed—one Strong Buy, two Buy, three Hold and one Sell—giving an average rating of Hold and an average price target of $2.03; recent notable moves include a downgrade to "sell" by Wall Street Zen and Barrington cutting its target to $1.50.
• OPKO last reported quarterly EPS of ($0.04) and revenue of $148.5M, both above estimates, but revenue fell 19.1% year-over-year and the company still posts negative margins and ROE; shares trade around $1.17 with a market cap near $888 million.

OPKO Health, Inc. (NASDAQ:OPK - Free Report) - Equities researchers at Zacks Research issued their FY2028 earnings per share (EPS) estimates for OPKO Health in a research report issued to clients and investors on Thursday, March 19th. Zacks Research analyst Team forecasts that the biotechnology company will post earnings per share of ($0.16) for the year. The consensus estimate for OPKO Health's current full-year earnings is ($0.25) per share.

A number of other brokerages also recently weighed in on OPK. Wall Street Zen downgraded OPKO Health from a "hold" rating to a "sell" rating in a report on Saturday, March 7th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of OPKO Health in a research report on Thursday, January 22nd. Barrington Research dropped their price objective on shares of OPKO Health from $2.25 to $1.50 and set an "outperform" rating on the stock in a research note on Monday, March 2nd. Finally, JPMorgan Chase & Co. started coverage on shares of OPKO Health in a research report on Thursday, November 20th. They issued a "neutral" rating for the company. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, OPKO Health has an average rating of "Hold" and an average target price of $2.03.

OPKO Health Stock Performance

Shares of NASDAQ OPK opened at $1.17 on Friday. The company has a current ratio of 3.97, a quick ratio of 3.52 and a debt-to-equity ratio of 0.26. OPKO Health has a one year low of $1.11 and a one year high of $1.86. The business has a 50-day moving average price of $1.24 and a two-hundred day moving average price of $1.34. The firm has a market capitalization of $888.11 million, a PE ratio of -3.90 and a beta of 1.50.

OPKO Health (NASDAQ:OPK - Get Free Report) last issued its quarterly earnings results on Thursday, February 26th. The biotechnology company reported ($0.04) earnings per share for the quarter, beating analysts' consensus estimates of ($0.07) by $0.03. The business had revenue of $148.50 million for the quarter, compared to the consensus estimate of $139.76 million. OPKO Health had a negative return on equity of 17.42% and a negative net margin of 37.19%.OPKO Health's revenue for the quarter was down 19.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.01 earnings per share.

Institutional Trading of OPKO Health

A number of institutional investors and hedge funds have recently made changes to their positions in OPK. Caprock Group LLC acquired a new position in shares of OPKO Health during the 3rd quarter valued at about $26,000. Swiss Life Asset Management Ltd bought a new position in shares of OPKO Health in the 3rd quarter valued at approximately $30,000. Zacks Investment Management acquired a new stake in OPKO Health in the 4th quarter worth approximately $27,000. Savant Capital LLC bought a new stake in OPKO Health during the third quarter worth approximately $33,000. Finally, StoneX Group Inc. bought a new stake in OPKO Health during the fourth quarter worth approximately $27,000. Institutional investors and hedge funds own 64.63% of the company's stock.

About OPKO Health

OPKO Health, Inc NASDAQ: OPK is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.